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Considering old GDM diagnostic criteria, alterations in insulin secretion and action are present in women with GDM as well as
in women with one abnormal value (OAV) during OGTT. Our aim is to assess if changes in insulin action and secretion during
pregnancy are related to 1-hour plasma glucose concentration during OGTT. We evaluated 3 h/100 g OGTT in 4,053 pregnant
women, dividing our population on the basis of 20mg/dL increment of plasma glucose concentration at 1h OGTT generating 5
groups (<120mg/dL, n = 661; 120–139mg/dL, n = 710; 140–159mg/dL, n = 912; 160–179mg/dL, n = 885; and ≥180mg/dL,
n = 996). We calculated incremental area under glucose (AUCgluc) and insulin curves (AUCins), indexes of insulin secretion
(HOMA-B), and insulin sensitivity (HOMA-R), AUCins/AUCgluc.A U C gluc and AUCins progressively increased according to 1-hour
plasma glucose concentrations (both P<0.0001 for trend). HOMA-B progressively declined (P<0.001), and HOMA-R pro-
gressively increased across the ﬁve groups. AUCins/AUCgluc decreased in a linear manner across the 5 groups (P<0.001). Analysing
the groups with 1-hour value <180mg/dL, defects in insulin secretion (HOMA-B: −29.7%) and sensitivity (HOMA-R: +15%) in-
dexes were still apparent (all P<0.001). Progressive increase in 1-hour OGTT is associated with deterioration of glucose tolerance
and alterations in indexes of insulin action and secretion.
1.Introduction
Pregnancy is characterized by a complex endocrine-meta-
bolicadaptationprocessincludingimpairedinsulinsensitivi-
ty, increased β-cell function, moderate elevation of blood
glucose levels, particularly following the ingestion of a meal,
and changes in the circulating levels of free fatty acids, tri-
glycerides, cholesterol, and phospholipids [1]. These changes
do not reﬂect a pathological condition; rather, they represent
a necessary and indispensable adaptation to meet the energy
demand of the foetus and to prepare the maternal organism
for delivery and lactation. However, in 3–5% of pregnant
women this physiologic adaptation [2] becomes abnormal
and gestational diabetes may develop. Therefore, a condition
that should result in healthy growth of the foetus, may turn
into a threatening condition for both the mother and her
baby. Most likely the development of gestational diabetes
reﬂects individual predisposition [2] because, in spite of
commonrestorationofnormalglucosetoleranceupondeliv-
ery,alargepercentageofthesewomenwilldevelopoverttype
2 diabetes later in life [3].
The importance of eﬀective and timely diagnosis has
been recognized and diagnostic criteria have been estab-
lished. According to the criteria proposed by Carpenter and
Coustan, gestational diabetes is diagnosed whenever, in re-
sponse to a 3-hour OGTT, two abnormal glucose levels are
recorded [4]. These criteria have been recently revisioned,
followingthereportoftheHAPOstudy[5]becausetherewas2 International Journal of Endocrinology
concern that full assessment of risk was not be suﬃciently
disclosed by old criteria. For instance, we have recently
shown that there is no much diﬀerence in insulin sensitivity
or insulin secretion between GDM women and those who
have only one abnormal value (i.e., not diagnostic for GDM)
[6]. These alterations were particularly apparent for eleva-
tions of the 1-hour plasma glucose than it was for other
OGTT time points, suggesting that this value may provide a
better parameter for risk stratiﬁcation. In order to assess this
hypothesis, we have reanalysed our cohort of pregnant wo-
menbyassessingchangesinindexesofinsulinactionandsec-
retionasafunctionofchangesof1-hourplasmaglucosecon-
centration in response to a 100g OGTT.
2.Research DesignandMethods
Thestudywasperformedonthesamecohortofourprevious
observation [6]. Brieﬂy, a total of 4,053 pregnant women
with positive glucose challenge test (GCT: plasma glucose
value ≥140mg/dL 1hr after a standard 50g glucose load)
carried out around the 27th week of gestation underwent a
3h 100g OGTT (samples: 0 , 1hr, 2hr, 3hr) for determina-
tion of plasma glucose and insulin concentrations.
On the morning of the test, demographic, anthropomet-
ric, and clinical data were recorded. Glucose tolerance was
deﬁned according to the criteria of Carpenter and Coustan
[4]. GDM was diagnosed when two or more plasma glucose
levels exceeded the cutoﬀ values; women with a single altered
value were classiﬁed as having OAV and women not meeting
any cutoﬀ values were considered normotolerant.
In the current analysis we have arbitrarily divided the
study population based on 20mg/dL increment of plasma
glucose concentration at 1-hour OGTT generating 5 groups
(<120mg/dL, n = 661; 120–139mg/dL, n = 710; 140–
159mg/dL,n = 912;160–179mg/dL,n = 885;and≥180mg/
dL n = 996).
The study was approved by local ethics committees and
women gave their written informed consent to the collection
of information, from their medical records.
2.1. Measurements and Statistical Analysis. Plasma glucose
levels were determined on a Beckman Glucose Analyzer
2 (Beckman, Fullerton, CA) based on the glucose oxidase
method and plasma insulin concentrations were measured
by radioimmunoassay (INSI-CTK Irma; Dia Sorin). The
inter- and intraassay coeﬃcients of variation for all param-
eters were ≤5%.
Incremental areas under the glucose curve (AUCgluc)a n d
insulin curve (AUCins) during the OGTT were calculated
using the trapezoidal rule. As a measure of insulin secretion,
basal insulin and glucose concentrations were used for the
estimation of β-cell secretion according to the homeostasis
modelassessment(HOMA-B)[7]:(20 ×Ins0)/(Gluc0 −3.5).
HOMA-R index was calculated [7] to reﬂect insulin action
in a manner independent of OGTT responses. We computed
AUCins/AUCgluc as generalized insulinogenic index.
Data are given as percentages or mean ± SD. ANOVA
with post hoc Bonferroni analysis was used to assess univari-
ate diﬀerences among continuous variables; for qualitative
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Figure 1: GDM and OAV prevalence according to 1-hour OGTT
plasma glycaemia. GDM: gestational diabetes mellitus; OAV: wo-
men with one abnormal value during OGTT. The prevalence of
GDM and OAV increases in the ﬁve groups of pregnant women
(both P<0.0001).
variables, we used the χ2 test to compare observed frequency
between groups. All statistical comparisons were considered
signiﬁcant at P<0.05. Statistical analyses were performed
using a statistical package (Statview SE; SAS Institute, Cary,
NC) on a Macintosh computer (Apple, Cupertino, CA).
3. Results
The main clinical characteristics of the 5 groups of ascending
1-hour plasma glucose are shown in Table 1. These 5 groups
were comparable for all parameters with the exception of
BMI although absolute diﬀerences did not exceed 1.2kg/m2.
Of interest, no diﬀerence was apparent in body weight gain
during pregnancy among the 5 groups. The prevalence of
GDM (0.3, 1.8, 3.9, 13.7, 80.3%) and that of one abnor-
mal value (including 1-hour, 2-hour, 3-hour OAV) progres-
sivelyincreasedinthe5groupsofpregnantwomen(bothP<
0.0001, Figure 1). Fasting glucose and insulin levels increas-
ed among the 5 groups as shown in Table 2 (P< 0,0001;
P<0,01, resp.). Accordingly, both AUCgluc and AUCins pro-
gressively increased over the spectrum of 1-hour plasma
glucose concentrations (AUCgluc from 8894 ± 1295mg/dL/
min to 14493 ± 1841mg/dL/min, AUCins from 6562 ±
3274pmol/l/minto9150±5516pmol/l/min;bothP<0.0001
for trend). Moreover, HOMA-R increased in a linear manner
from the group with the lowest to the one with the highest 1-
hour plasma glucose level (P<0,001) (Figure 2). HOMA-B
progressively declined (P<0.001) over the entire spectrum
(Figure 3(a)). AUCins/AUCgluc decreased in a linear manner
across the 5 groups (from 13,19 ± 6.59 to 11,24 ± 6.53,
P<0,001, Figure 3(b)). When the analysis was restricted to
groupswith1-hourplasmaglucose<180mg/dL,theprogres-
sivenatureofdefectsininsulinsecretion(HOMA-B:−29.7%)International Journal of Endocrinology 3
Table 1: Clinical features of pregnant women related to 1-hour glucose values during OGTT (data are means ± SD).
1h glycaemia (mg/dL) <120 120–139 140–159 160–179 ≥180 ANOVA (P)
N 661 710 912 885 886
Age (years) 30.7 ±43 1 .1 ±43 1 .7 ±43 2 .1 ±43 2 .2 ±4N S
Prepregnancy weight (kg) 64.9 ±10 63.5 ±96 4 .3 ±11 65.1 ±12 66.2 ±12 <0.001
Prepregnancy BMI (kg/m2)2 4 .4 ±3.82 3 .7 ±3.62 4 ±4.22 4 .3 ±4.62 4 .9 ±4.4 <0.01
Weight gain (kg) 7.5 ±3.47 .7 ±3.37 .5 ±3.37 .7 ±3.57 .7 ±3.6N S
Systolic BP (mmHg) 116.8 ±11 115.1 ±10 116 ±12 114.8 ±12 116.7 ±12 NS
Diastolic BP (mmHg) 71.9 ±87 1 .4 ±87 1 .28 7 1 .1 ±87 1 .7 ±8N S
Total cholesterol (mg/dL) 261 ±45 258 ±46 257 ±44 254 ±39 263 ±50 NS
LDL cholesterol (mg/dL) 160 ±43 179 ±32 162 ±36 166 ±45 166 ±40 NS
HDL cholesterol (mg/dL) 54.3 ±18 58.3 ±18 59.2 ±20 61.1 ±18 62.2 ±19 NS
Triglycerides (mg/dL) 199 ±67 205 ±81 201 ±66 191 ±79 197 ±77 NS
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Figure 2: HOMA-R index according to 1-hour OGTT plasma gly-
caemia. HOMA-R index is estimated using the formulas proposed
by Matthews et al. [7].
and insulin sensitivity (HOMA-R: +15%) were still apparent
(all P<0.001).
4. Discussion
Although gestational diabetes is a well-recognized condition
that may aﬀect maternal and foetus health state, evidence is
mounting that nondiabetic abnormalities of glucose home-
ostasis should be looked at with some caution [8, 9]. Carr
et al. [10] have shown that pregnant women with OAV have
twofold greater risk for subsequent diabetes as compared to
women with no abnormal values in response to an OGTT.
More recently, the HAPO study (Hyperglycemia and Adverse
Pregnancy Outcome) [5], a clinical trial conducted on a
large cohort of pregnant women aimed at clarifying the
risk of adverse outcomes associated with various nondiabetic
degrees of maternal glucose intolerance, showed a strong,
continuous association between maternal glucose levels and
increased birth weight as well as poor pregnancy outcomes.
Moreover, among pregnant women with OAV, the alteration
of1-hourplasmaglucoseseemstoprovidethebestpredictive
eﬀect in terms of both pathophysiologic involvement and
clinical outcome as initially highlighted by Retnakaran and
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Figure 3: HOMA-B index and AUCins/AUCgluc according to 1-hour
OGTT plasma glycaemia. HOMA-B index is estimated using the
formulas proposed by Matthews et al. [7].
colleagues [11]. In their paper they showed that all measures
of severity of glycemic control were highest in women with
GDM group, followed by the 1-hour OAV, 2-hour or 3-
hour OAV, and NGT groups. Consistent with this ﬁnd-
ing, insulin sensitivity was highest in the NGT group and
worsened in a progressive manner through the 2-hour or 3-
hourOAV,1-hOAV,andGDMgroups.Inourpreviousstudy,
we showed that pregnant women with 1-hour OAV also4 International Journal of Endocrinology
Table 2: Fasting glucose and insulin levels related to 1-hour glucose values during OGTT (data are means ± SD).
1h glycaemia (mg/dL) <120 120–139 140–159 160–179 ≥180 ANOVA (P)
Fasting glucose (mg/dL) 72.4 ±10.48 0 .8 ±9.14 82.11±9.16 84.1 ±10 87.5 ±11 <0.0001
Fasting insulin (pmol/L) 55.19±29.55 7 .5 ±36.66 1 .8 ±47 63.5 ±53 67.7 ±51 <0.01
had a greater impairment in their measures of β-cell func-
tion [6]. Moreover, pregnant women with 1-hour OAV,
compared with those with 2-hour or 3-hour OAV, have a
higher prevalence of adverse obstetric outcome, including
caesarean delivery, macrosomia, and hypertensive disorder
[12]. Finally, 3 months after delivery, women with 1-hour
OAV tend to have persistent metabolic dysfunction, includ-
ing higher plasma glucose levels, greater insulin resistance,
and poorer β-cell function, very much alike women with
prior GDM [13].
In summary, 1-hour OAV in pregnant women may be
used for the stratiﬁcation of the pregnancy risk. In order to
gain further insights in the signiﬁcance of 1-hour glucose, we
have reanalyzed data from a large cohort of pregnant women
showing that the progressive increase in this parameter is
associated with a progressive loss of β-cell function as well
as a decline in insulin sensitivity. Moreover the deterioration
of the two main homeostatic parameters becomes apparent
wellwithintheso-callednormalrangeofglucosetolerancein
pregnancy. We would underline that in the same range (i.e.,
1h glucose values <120mg/dL) GDM (0,3%) and OAV (4%)
werealsopresentandtheirprevalenceprogressivelyincreases
according to 1h glucose values. These data suggest that even
in categories with normal or very low 1-hour glucose values
an alteration in glucose homeostasis is already apparent.
This also raises the question on the reason for 1-hour
plasma glucose value to be so linked to degeneration of
glucose homeostatic mechanisms. Although not directly
assessedinthepresentstudy,ithasalreadybeenreportedthat
innondiabeticindividuals,theprogressiveincreaseofplasma
glucose concentration at 30–60min after an OGTT is depen-
dent on β-cell function and insulin sensitivity in peripheral
tissues [14, 15]. Therefore, it is plausible that development
of insulin resistance in the liver and in the skeletal muscle
and concomitant weakening of insulin secretion will result
in progressive elevation of 1-hour glucose concentration, as
suggested by our results. Moreover, in nondiabetic individu-
als it has been shown that 1-hour plasma glucose concentra-
tion has a stronger correlation with surrogates measures of
hepatic and muscle insulin resistance and β-cell dysfunction
compared with 2-hour plasma glucose levels [16].
The 1-hour plasma glucose value has been advocated as
a risk marker not only in pregnant women. Abdul-Ghani
et al. [17] have shown that the plasma glucose concentration
at 1-hour after an OGTT is a powerful predictor of future
risk for type 2 diabetes. He was also proposing a cutoﬀ
point of 155/mL dL to stratify diabetes risk. Moreover,
Succurro et al. [18]haverecentlyshownthatindividualswith
normal glucose tolerance but a 1-hour plasma glucose levels
≥155mg/dL have an atherogenic proﬁle similar to IGT sub-
jects. Obviously, we cannot extrapolate the continuous
relationship between 1-hour plasma glucose levels and
alterations in insulin action and secretion to the general
population, but the strong similarities existing between
GDM and IGT/type 2 diabetes are worth being considered.
Our data, indeed, strongly suggest that alterations in glucose
homeostasis related to increasing t 1-hour plasma glucose
value are continuous variables: for each 20mg/dL increase in
1-hour plasma glucose concentration there is a concomitant
impairment in insulin action and a reduction in insulin
secretion.
A limitation of our study should be represented by the
indexes we used to determine insulin secretion and action
that involve only basal glucose and insulin concentration;
anyway, these indexes decrease as 1h glucose value increases.
In conclusion, this study underlines the concept that
the spectrum of glucose tolerance in pregnancy identiﬁes a
continuum of disturbance of glucose homeostasis and that
1-hour glucose level after 100g OGTT may be considered a
relevant marker for improving risk stratiﬁcation in pregnant
women. Moreover, although new IADPSG criteria for GDM
diagnosis [19] erase the diﬀerence between GDM and OAV,
the importance of 1-hour glucose level impairment still re-
mains and our data reinforce the concept that the new low-
er diagnostic criteria will be useful in reducing the risk for
short- (obstetrical) and long-term (metabolic and cardiovas-
cular) complications.
Abbreviations
OGTT: Oral glucose tolerance test
1h OGTT: 1-hour during OGTT
GDM: Gestational diabetes
OAV: One abnormal value
AUCgluc: Area under glucose curve
AUCins: Area under insulin curve
HOMA-B: Index of insulin secretion (homeostasis
model assessment: β cell function)
HOMA R: Index of insulin sensitivity (homeostasis
model assessment:insulin resistance).
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